A New Combination of Factor XA Inhibition and Standard Antiplatelet Therapy to Prevent More Recurrent Cardiovascular Events in Acute Coronary Syndrome (ACS) - European Medical Journal
×

Browse

A New Combination of Factor XA Inhibition and Standard Antiplatelet Therapy to Prevent More Recurrent Cardiovascular Events in Acute Coronary Syndrome (ACS)

Download as | PDF
Speakers:
Christoph Bode,1 Gabriel Steg,2 Gilles Montalescot,3 Robert Welsh4
Disclosure:

The speakers were contracted by EuroPCR to participate in this satellite symposium.

Acknowledgements:

Writing assistance provided by Trilogy Writing and Consulting Ltd.

Support:

The publication of this article was funded by Bayer HealthCare Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Bayer.

Citation
EMJ Int Cardiol. ;1[1]:20-33.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The purpose of this symposium was to:

  • Discuss the interplay between the coagulation cascade and platelets in arterial thrombus formation.
  • Present the rationale for oral antiplatelet and anticoagulant therapy to reduce residual thrombotic risk in patients following Acute Coronary Syndrome (ACS).
  • Discuss the significant benefits seen in patients following ACS when combining rivaroxaban 2.5 mg twice daily with standard antiplatelet therapy.
  • Assess how the use of oral anticoagulation may change current standards of care and influence guidelines in patients with ACS.

Please view the full content in the pdf above.